GlassScriptPhysician profile
Anthony V Songco
NPI 1508025909
$5,109.84
in general payments reported to CMS, 2019-2025
29 companies · $950 in 2025
The $950 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $548 · 2020: $211 · 2021: $395 · 2022: $1,099 · 2023: $1,057 · 2024: $850 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,856.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $655.26 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $530.49 | 2019-2025 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $509.65 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $505.86 | 2021-2025 | Verquvo |
| Kestra Medical Technology Services, INC. | $473.83 | 2022-2024 | Assure Wcd |
| Astrazeneca Pharmaceuticals LP | $301.55 | 2019-2024 | Farxiga, Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.15 | 2022-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $250.39 | 2019-2023 | Xarelto |
| Abbott Laboratories | $228.90 | 2021-2022 | |
| Abiomed | $219.49 | 2020-2025 | |
| Stryker Corporation | $156.17 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Inari Medical, INC. | $142.68 | 2022 | |
| Heartflow, INC. | $120.47 | 2024 | |
| Pfizer INC. | $118.87 | 2019-2025 | |
| Chiesi USA, INC. | $114.67 | 2020-2025 | Kengreal, Cleviprex |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $108.06 | 2019-2025 | Repatha, Repatha |
| Novo Nordisk INC | $64.33 | 2019-2023 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $48.62 | 2023-2024 | Watchman, Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $40.75 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $38.60 | 2019-2022 | |
| Teleflex LLC | $34.77 | 2024-2025 | Langston, Guideliner |
| Philips North America LLC | $29.01 | 2023 | |
| Scpharmaceuticals INC. | $27.71 | 2024 | |
| Bridgebio Pharma, INC. | $25.29 | 2025 | Attruby |
| Inspire Medical Systems, INC. | $17.78 | 2024 | Inspire |
| Cordis US Corp. | $17.55 | 2024 | Infiniti |
| Amarin Pharma, INC. | $17.34 | 2022 | |
| Edwards Lifesciences Corporation | $15.45 | 2022 | |
| Daiichi Sankyo INC. | $12.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Songco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.